Treatment of chronic non-infectious uveitis and scleritis.

Détails

Ressource 1Télécharger: 30852832.pdf (497.89 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_CEF6ECB55ECE
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Treatment of chronic non-infectious uveitis and scleritis.
Périodique
Swiss medical weekly
Auteur⸱e⸱s
Rossi D.C., Ribi C., Guex-Crosier Y.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
25/02/2019
Peer-reviewed
Oui
Volume
149
Pages
w20025
Langue
anglais
Notes
Publication types: Journal Article ; Systematic Review
Publication Status: epublish
Résumé
Ocular inflammations such as uveitis and scleritis can lead to significant visual impairment if not treated properly. To limit potentially sight-threatening complications, good control of the inflammation in the acute phase is necessary. Corticosteroids have been the mainstay of ocular therapies for many years, but high doses of corticosteroids, which are required to maintain quiescence in severe uveitis, can be associated with many systemic and ocular complications. In order to limit steroid side-effects, classic immunosuppressant and immunobiologic agents have been widely used as steroid-sparing agents. In this review, we summarise the immunosuppressive drug therapy utilised in the treatment of ocular inflammatory diseases.
Mots-clé
Adrenal Cortex Hormones/adverse effects, Adrenal Cortex Hormones/therapeutic use, Azathioprine/therapeutic use, Cyclosporine/therapeutic use, Enzyme Inhibitors/therapeutic use, Immunosuppressive Agents/therapeutic use, Methotrexate/therapeutic use, Mycophenolic Acid/therapeutic use, Scleritis/drug therapy, Uveitis/drug therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/04/2019 16:08
Dernière modification de la notice
13/04/2024 6:17
Données d'usage